Literature DB >> 29125047

Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital.

David L Ain1, Mazen Albaghdadi2, Jay Giri1, Farhad Abtahian3, Michael R Jaff4, Kenneth Rosenfield2, Nathalie Roy5, Mauricio Villavicencio-Theoduloz5, Thoralf Sundt5, Ido Weinberg2.   

Abstract

Mortality associated with high-risk pulmonary embolism (PE) remains high. Extra-corporeal membrane oxygenation (ECMO) allows for acute hemodynamic stabilization and potentially for administration of other disease process altering therapies. We sought to compare two eras: pre-ECMO and post-ECMO in relation to high-risk PE treatment and mortality. A single-center retrospective chart review was conducted of high-risk PE patients. High-risk PE was defined as acute PE and cardiac arrest or shock. A total of 60 patients were identified, 31 in the pre-ECMO era and 29 in the post-ECMO era. Mean age was 56.1±21.1 years and 51.7% were women. More patients in the post-ECMO era were identified with computed tomography (82.8% vs 51.6%, p=0.011) and more patients in the post-ECMO era had right ventricular dysfunction on echocardiography (96.4% vs 78.3%, p=0.045). No other differences were noted in baseline characteristics or clinical, laboratory and imaging data between the two groups. In total, ECMO was used in 13 (44.8%) patients in the post-ECMO era. There was greater utilization of catheter-directed therapies in the post-ECMO era compared to the pre-ECMO era ( n = 7 (24.1%) vs n = 1 (3.2%), p=0.024). Thirty-day survival increased from 17.2% in patients who presented in the pre-ECMO era to 41.4% in the post-ECMO era ( p=0.043). While more work is necessary to better identify those PE patients who stand to benefit from mechanical circulatory support, our findings have important implications for the management of such patients.

Entities:  

Keywords:  extra-corporeal membrane oxygenation (ECMO); outcomes; pulmonary embolism (PE)

Mesh:

Year:  2017        PMID: 29125047     DOI: 10.1177/1358863X17739697

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  5 in total

Review 1.  Management of Acute Pulmonary Embolism.

Authors:  Connor Tice; Matthew Seigerman; Paul Fiorilli; Steven C Pugliese; Sameer Khandhar; Jay Giri; Taisei Kobayashi
Journal:  Curr Cardiovasc Risk Rep       Date:  2020-10-06

2.  National trends and outcomes for extra-corporeal membrane oxygenation use in high-risk pulmonary embolism.

Authors:  Ayman Elbadawi; Amgad Mentias; Islam Y Elgendy; Ahmed H Mohamed; Mohammed Hz Syed; Gbolahan O Ogunbayo; Odunayo Olorunfemi; Igor Gosev; Sunil Prasad; Scott J Cameron
Journal:  Vasc Med       Date:  2019-03-05       Impact factor: 3.239

3.  Decompressive laparotomy for a patient on VA-ECMO for massive pulmonary embolism that suffered traumatic liver laceration after mechanical CPR.

Authors:  Jaideep Das Gupta; Ramses Saavedra; Sundeep Guliani; John Marinaro; Muhammad Ali Rana
Journal:  J Surg Case Rep       Date:  2018-10-31

4.  Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium.

Authors:  Belinda Rivera-Lebron; Michael McDaniel; Kamran Ahrar; Abdulah Alrifai; David M Dudzinski; Christina Fanola; Danielle Blais; David Janicke; Roman Melamed; Kerry Mohrien; Elizabeth Rozycki; Charles B Ross; Andrew J Klein; Parth Rali; Nicholas R Teman; Leoara Yarboro; Eugene Ichinose; Aditya M Sharma; Jason A Bartos; Mahir Elder; Brent Keeling; Harold Palevsky; Soophia Naydenov; Parijat Sen; Nancy Amoroso; Josanna M Rodriguez-Lopez; George A Davis; Rachel Rosovsky; Kenneth Rosenfield; Christopher Kabrhel; James Horowitz; Jay S Giri; Victor Tapson; Richard Channick
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 5.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2020-04-17       Impact factor: 24.094

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.